What the GIP component of tirzepatide is thought to contribute, and how confident we can be — the long version posts 31–53
This is a continuation of a long topic, addressed by post number rather than by page. Start at post 1 · go to the accepted answer.
On the mechanism question specifically: the honest position is that GIP agonism plausibly contributes and that the trial design cannot separate its contribution from simply achieving greater receptor engagement overall.
I would put a moderate confidence on that and no more.
Post #33 answers the question as asked. The question underneath it is different.
On purity: the trailing-edge features people report on tirzepatide chromatograms are frequently deamidation products, which elute close to the main peak and are easy to integrate into it. That is a method question rather than a quality question.
I checked the source rather than the summary, and they differ.
Picking up post #33: that is the part I would want checked first.
Worth stating the null on GIP component of tirzepatide before we explain it: the observation may be nothing. That possibility deserves a sentence and usually does not get one.
Two claims get bundled together under GIP component of tirzepatide and they need separating. The descriptive one — this is what was observed — is usually well supported. The causal one — this is why — usually is not.
Almost every disagreement in threads like this one dissolves once you say which of the two you are making.
Collapsed as off-topic by two members at trust level 3 or above
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
Marking that as an opinion rather than a finding.
Comparisons between the tirzepatide and semaglutide programmes across trials rather than within one are weak. Different populations, different durations, different baseline characteristics; the only fair comparison is a head-to-head one.
I would put the burden of proof on the interesting explanation, not the dull one.
The five maintenance doses in the tirzepatide programme give a genuine dose-response curve, which is unusual. Most trials in this space compare one or two doses against placebo and cannot say anything about the shape of the relationship.
A single observation, in a thread that deserves better than single observations.
Appreciated. The plain phrasing does more work here than a longer post would.
Post #40 and I disagree about the size of the effect, not about the direction.
On GIP component of tirzepatide: the maintained page in the documentation commons covers the general case with citations and a review date, which is more reliable than any reply here including this one.
Dual agonism versus dose: how much of tirzepatide's effect is the GIP component and how much is simply achieving higher receptor engagement? The honest answer is that the question is not settled. Some of the effect is surely the GIP component, but the trial design does not decompose it.
The dual agonism is not a marketing framing — GIP receptor and GLP-1 receptor engagement are both demonstrable. What is genuinely unresolved is how much of the clinical effect the GIP limb contributes, because no trial decomposes it.
Old habit: I write down the expected answer before I calculate it.
Collapsed as off-topic by two members at trust level 3 or above
Building on post #42 rather than restating it.
Half-life difference: tirzepatide is about 5 days versus semaglutide's week-long. Practically, that means steady state is reached slightly faster and the post-dose swing is slightly larger. Most people do not report noticing the difference in practical terms.
SURPASS-2 compared tirzepatide with semaglutide 1.0 mg, the licensed diabetes dose at that time. It did not compare with semaglutide 2.4 mg, the highest approved dose. That is the central and legitimate criticism of the head-to-head evidence and it is worth remembering when people quote the trial.
That is the version I would defend. It is not the version I started with.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
The general answer and the answer for your case may diverge here.
Heart rate rises modestly across this class, tirzepatide included. It is consistent, small, and worth knowing about rather than worth alarm — and it is one of the reasons the trials monitored it explicitly.
I have no interest in any supplier named above.
Mass and charge states: tirzepatide is about 4813.5 Da and on an electrospray instrument you would expect to see charge states mostly in the 2+ to 4+ range, the same as semaglutide. A doubly charged species would appear at about (4813.5 + 2 × 1.008) / 2 ≈ 2408.
Reading it back, the second half matters more than the first.
Agreed, and I will stop repeating the version of this I had been repeating.
Collapsed as off-topic by two members at trust level 3 or above
Where I part company with post #47, and it is a narrow parting.
GIP component of tirzepatide came up in a thread eighteen months ago and was answered well. I cannot find it, which is itself the problem, so here is the reconstruction.
Post #49 is the version of this I will quote in future. One addition.
The GIP component: GIP receptor agonism is thought to amplify the GLP-1 effect on satiety and energy expenditure, but how much of tirzepatide's effect is that and how much is simply achieving higher receptor occupancy remains genuinely open. The mechanistic literature is active.
If that reads as pedantic, it is, and it has saved me twice.
Tirzepatide's half-life of roughly five days means steady state is approached in about three weeks rather than four. That is a real difference from semaglutide and it is small enough that the weekly schedule is unaffected.
It is the sort of thing that seems obvious in retrospect and was not at the time.
Suggested topics
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Tirzepatide's shorter half-life and its one practical consequence
On the subject in the title: Tirzepatide's shorter half-life and its one practical consequence Working notes rather than a conclusion. Documentation question rather than a pharmacological one, but about this…
|
+18 | 29 | 20k | 8mo |
|
Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA
Posting this under the heading it deserves: Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Everything below is what sits behind that. Reading back through what has been written here about…
|
+4 | 8 | 14k | 8mo |
|
Tirzepatide storage and stability: what is published versus what is assumed
On the subject in the title: Tirzepatide storage and stability: what is published versus what is assumed Working notes rather than a conclusion. Asking about tirzepatide storage and stability directly,…
|
+17 | 21 | 17k | 12d |
|
[2026 update] Does dual agonism explain the effect size, or is it dose?
Asking directly, because I could not find a straight answer: Does dual agonism explain the effect size, or is it dose? A question about dual agonism that I think has a definite answer, unlike most of what I…
|
+58 | 63 | 40k | 9mo |
|
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's
Revisiting: Why tirzepatide titration schedules have more steps than semaglutide's Writing it up because I had to work it out twice and would rather nobody else did. I would like to know what people here…
|
+89 | 101 | 32k | 8mo |
Related topics — sharing the tags SURMOUNT programme, randomised trial, effect size
| Topic | Participants | Replies | Views | Activity |
|---|---|---|---|---|
|
Amylin receptor signalling and satiety — what changed since
On the subject in the title: Amylin receptor signalling and satiety — what changed since Working notes rather than a conclusion. What changes if the standard account of Amylin receptor signalling and satiety…
|
+73 | 78 | 3.5k | 2mo |
|
Journal club: STEP 4 and what a withdrawal design can prove
On the subject in the title: Journal club: STEP 4 and what a withdrawal design can prove Working notes rather than a conclusion. Session topic: STEP 4 ( JAMA , 2021). Please read it before posting; the…
|
+61 | 65 | 2k | 13mo |
|
A preprint whose numbers changed substantially at publication
A preprint whose numbers changed substantially at publication — setting out what I have, and where I think it stops being reliable. A preprint question rather than a question about the finding in it. The…
|
+90 | 95 | 21k | 9mo |
|
Second pass at: Retatrutide dose escalation in the published trials
Second pass at: Retatrutide dose escalation in the published trials — setting out what I have, and where I think it stops being reliable. Two things I would like separated before anyone answers on Retatrutide…
|
+115 | 125 | 30k | 2y |
|
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version
Retatrutide's phase 2 heart-rate signal and how to think about it — the long version Writing it up because I had to work it out twice and would rather nobody else did. Putting the numbers in the first post,…
|
2 | 103 | 17mo |